TransCode Therapeutics, Inc. (NASDAQ: RNAZ), a clinical stage immuno-oncology company developing RNA-based treatments for high-risk and advanced cancers, announced the retirement of Chief Financial Officer Tom Fitzgerald and the immediate appointment of John Tattory as interim CFO. The leadership transition comes as the company continues to advance its pipeline of novel cancer therapies.
Fitzgerald has served as CFO since July 2018 and will also resign from the board of directors effective immediately. He will remain involved with the company in a transitional capacity to ensure a smooth handover of responsibilities. His departure marks the end of a tenure that spanned critical phases of TransCode's growth, including its public listing and ongoing clinical development efforts.
John Tattory brings over 25 years of financial and operational management experience across the pharmaceutical, medical device, and biotechnology sectors. His background includes roles at several prominent organizations, such as Ernst & Young LLP, Bristol-Myers Squibb, Tyco International, Cerapedics, and Windtree Therapeutics. Currently, Tattory serves as a managing director at Stout Risius Ross, where he provides consulting CFO services primarily to privately held life science companies. His deep expertise in financial strategy and life sciences is expected to be instrumental as TransCode navigates the complexities of clinical-stage development and potential commercialization.
The appointment of Tattory as interim CFO is a strategic move to maintain financial stability and momentum. TransCode's lead therapeutic candidate, TTX-MC138, targets metastatic tumors that overexpress microRNA-10b, a well-documented biomarker of metastasis. The company also has a portfolio of first-in-class candidates designed to mobilize the immune system against cancer cells. With Tattory's guidance, TransCode aims to continue its mission of pioneering innovative treatments for high-risk and advanced cancers.
For investors and stakeholders, the transition underscores the company's commitment to strong financial stewardship during a pivotal period. As TransCode advances its clinical programs, having experienced leadership in the CFO role is critical for managing resources, engaging with investors, and potentially securing additional funding. The news of Fitzgerald's retirement and Tattory's appointment may be viewed as a seamless succession plan that minimizes disruption.
To view the full press release, visit https://nnw.fm/8G3ik. The latest news and updates relating to RNAZ are available in the company's newsroom at https://nnw.fm/RNAZ. For more information about NetworkNewsWire, visit https://www.NetworkNewsWire.com.
